| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866584 | VEROSCIENCE | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov, 2012
(11 years ago) | |
| US5756513 | VEROSCIENCE | Therapeutic process for the treatment of the pathologies of type II diabetes |
Nov, 2012
(11 years ago) | |
| US5468755 | VEROSCIENCE | Therapeutic process for the treatment of the pathologies of Type II diabetes |
Nov, 2012
(11 years ago) | |
| US5679685 | VEROSCIENCE | Accelerated release composition containing bromocriptine |
Oct, 2014
(9 years ago) | |
| US5716957 | VEROSCIENCE | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
Feb, 2015
(9 years ago) | |
| US8137992 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(9 months ago) | |
| US8137993 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(9 months ago) | |
| US7888310 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy |
Jul, 2023
(9 months ago) | |
| US8137994 | VEROSCIENCE | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
Jul, 2023
(9 months ago) | |
| US9352025 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US10688155 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US9895422 | VEROSCIENCE | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US8877708 | VEROSCIENCE | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
Jun, 2030
(6 years from now) | |
| US8613947 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US8431155 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9700555 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US10688094 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9993474 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9522117 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US11000522 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
| US9192576 | VEROSCIENCE | Bromocriptine formulations |
Apr, 2032
(8 years from now) | |
Cycloset is owned by Veroscience.
Cycloset contains Bromocriptine Mesylate.
Cycloset has a total of 21 drug patents out of which 9 drug patents have expired.
Expired drug patents of Cycloset are:
- US5866584
- US5756513
- US5468755
- US5679685
- US5716957
- US8137992
- US8137993
- US7888310
- US8137994
Cycloset was authorised for market use on 05 May, 2009.
Cycloset is available in tablet;oral dosage forms.
Cycloset can be used as improvement of glycemic control in individuals with type 2 diabetes, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wherein the effects are as recited in claims 3-7, treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 52 wherein the effects are as recited in said claims, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29, adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24, improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors.
The generics of Cycloset are possible to be released after 30 April, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2012 |
Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient
Market Authorisation Date: 05 May, 2009
Treatment: Improvement of glycemic control in individuals with type 2 diabetes; Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors; Ad...
Dosage: TABLET;ORAL
CYCLOSET family patents
